Congestive Heart Failure Treatment Devices Market Size, Share and Growth Outlook, 2026

Congestive Heart Failure Treatment Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Congestive Heart Failure Treatment Devices Market size is forecast to increase from $7.58 Billion in 2026 to $12.93 Billion in 2034 at a CAGR of 6.9% between 2026 and 2034.

The Congestive Heart Failure Treatment Devices market report provides detailed analysis and outlook of Congestive Heart Failure Treatment Devices segments including By Product Type (Ventricular Assist Devices, Cardiac Resynchronization Therapy, Implantable Cardioverter-Defibrillators, Pacemakers, Counter-Pulsation Devices, Total Artificial Hearts ), By Application (Left Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist Device ), By End User (Hospitals, Specialty Cardiac Centers, Ambulatory Surgical Centers, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Congestive Heart Failure Treatment Devices Industry Overview

Baroreflex Activation Therapy Advancing Device-Based Heart Failure Treatment

The congestive heart failure treatment devices industry is evolving through the development of advanced device-based therapies designed to improve cardiovascular function and disease management. A major area of focus is Baroreflex Activation Therapy (BAT), which is being evaluated in the ongoing BENEFIT-HF clinical trial sponsored by CVRx, Inc. The study is assessing the long-term safety and effectiveness of the Barostim system for patients with New York Heart Association (NYHA) Functional Class II and III heart failure. The trial represents one of the most significant efforts to evaluate neuromodulation-based therapy for chronic heart failure management. By stimulating baroreceptors involved in cardiovascular regulation, BAT aims to improve autonomic balance and alleviate symptoms associated with heart failure, expanding the range of treatment options available beyond conventional pharmacological interventions.

Artificial Intelligence Enhancing Early Detection and Clinical Decision Support

Artificial intelligence is becoming a critical component of the congestive heart failure treatment devices industry. Cardiovascular AI developer Anumana received FDA 510(k) clearance for advanced software-as-a-medical-device cardiovascular algorithms that support early identification of heart failure-related conditions. Building upon its ECG-AI LEF technology, which transforms standard 12-lead electrocardiograms to evaluate left ventricular dysfunction, the company secured clearance for its pulmonary hypertension algorithm. Developed using more than 250,000 patient records from the Mayo Clinic, these AI-powered solutions integrate directly into healthcare systems and provide real-time clinical decision support. The technology is designed to identify heart strain patterns and cardiovascular abnormalities before clinical decompensation occurs, enabling earlier intervention and improved disease monitoring across heart failure care pathways.

Home-Based Monitoring and Wearable Therapies Transforming CHF Management

The industry is increasingly moving toward remote patient management solutions that reduce dependence on hospital-based care. Swiss medical device company SQ Innovation obtained FDA approval for a reusable wearable infuser system designed to deliver controlled subcutaneous diuretic therapy for patients experiencing acute edema associated with congestive heart failure. The device enables patients to manage fluid retention at home, reducing the need for hospital admissions and supporting more continuous disease management. Similarly, Heartfelt demonstrated the predictive capabilities of its HF-3 home-monitoring device through results from the FOOT multi-center clinical trial. The system utilizes standalone 3D imaging sensors and artificial intelligence algorithms positioned within the home to monitor subtle changes in peripheral edema in the feet and legs. By providing automated risk alerts to care teams and serving as a high-adherence alternative to traditional weight-based monitoring, these technologies are reshaping remote heart failure management and enabling earlier identification of decompensation risks.

Congestive Heart Failure Treatment Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Congestive Heart Failure Treatment Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Jarvik Heart, Inc., CVRx, Inc., Abiomed (Johnson & Johnson), Terumo Corporation, Berlin Heart GmbH. The Congestive Heart Failure Treatment Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Congestive Heart Failure Treatment Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Congestive Heart Failure Treatment Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Congestive Heart Failure Treatment Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Congestive Heart Failure Treatment Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Congestive Heart Failure Treatment Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Congestive Heart Failure Treatment Devices industry include- Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Jarvik Heart, Inc., CVRx, Inc., Abiomed (Johnson & Johnson), Terumo Corporation, Berlin Heart GmbH. The Congestive Heart Failure Treatment Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Congestive Heart Failure Treatment Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Congestive Heart Failure Treatment Devices market remains one of the strongest-performing segments in the country.
The US Congestive Heart Failure Treatment Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Congestive Heart Failure Treatment Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Congestive Heart Failure Treatment Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Congestive Heart Failure Treatment Devices markets

Canada's strong Congestive Heart Failure Treatment Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Congestive Heart Failure Treatment Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Congestive Heart Failure Treatment Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Congestive Heart Failure Treatment Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Congestive Heart Failure Treatment Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Congestive Heart Failure Treatment Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Congestive Heart Failure Treatment Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Congestive Heart Failure Treatment Devices sales through 2034

France Congestive Heart Failure Treatment Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Congestive Heart Failure Treatment Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Congestive Heart Failure Treatment Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Congestive Heart Failure Treatment Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Congestive Heart Failure Treatment Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Congestive Heart Failure Treatment Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Congestive Heart Failure Treatment Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Congestive Heart Failure Treatment Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Congestive Heart Failure Treatment Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Congestive Heart Failure Treatment Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Congestive Heart Failure Treatment Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Congestive Heart Failure Treatment Devices Market Segmentation

By Product Type
Ventricular Assist Devices
Cardiac Resynchronization Therapy
Implantable Cardioverter-Defibrillators
Pacemakers
Counter-Pulsation Devices
Total Artificial Hearts
By Application
Left Ventricular Assist Device
Right Ventricular Assist Device
Biventricular Assist Device
By End User
Hospitals
Specialty Cardiac Centers
Ambulatory Surgical Centers
Diagnostic Centers

Top Companies in Congestive Heart Failure Treatment Devices Industry

Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
Biotronik SE & Co. KG
LivaNova PLC
Jarvik Heart, Inc.
CVRx, Inc.
Abiomed (Johnson & Johnson)
Terumo Corporation
Berlin Heart GmbH

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025